2145115-85-9
2145115-85-9
Chemical Structure
Praluzatamab ravtansine
Synonym(s): CX-2009; CD166
- CAS. Nr.: 2145115-85-9
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Praluzatamab ravtansine]
Biological Activity: Praluzatamab ravtansine (CX-2009) is an anti-CD166 antibody drug conjugate (ADC) with an Kd value of 25.15 nM. Praluzatamab ravtansine contains an anti-CD166 monoclonal antibody Praluzatamab (HY-P99788) conjugated to the microtubule inhibitor DM4 (HY-12454). Praluzatamab ravtansine shows tumor targeting and can be used for the study of lung cancer and breast cancer[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Praluzatamab ravtansine | 99.07% | Praluzatamab ravtansine (CX-2009) is an anti-CD166 antibody drug conjugate (ADC) with an Kd value of 25.15 nM. Praluzatamab ravtansine contains an anti-CD166 monoclonal antibody Praluzatamab (HY-P99788) conjugated to the microtubule inhibitor DM4 (HY-12454). Praluzatamab ravtansine shows tumor targeting and can be used for the study of lung cancer and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Boni V, et al. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 May 13;28(10):2020-2029. [Content Brief]
- [2]. Chomet M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice. Theranostics. 2020 Apr 27;10(13):5815-5828. [Content Brief]
